Compounded Semaglutide alternatives — when to consider switching
If Compounded Semaglutideisn't working as expected, isn't covered by your insurance, side effects are intolerable, or you want to try something with different efficacy profile, several FDA-approved alternatives exist within the GLP-1 family. This page compares each on efficacy, dosing schedule, cost, and switching considerations.
The GLP-1 family — your alternatives
Single GLP-1 receptor agonists
- Semaglutide (Ozempic for diabetes, Wegovy for weight loss, Rybelsus oral) — Novo Nordisk
- Liraglutide (Victoza for diabetes, Saxenda for weight loss) — Novo Nordisk
- Dulaglutide (Trulicity for diabetes) — Eli Lilly
- Exenatide (Byetta, Bydureon for diabetes) — AstraZeneca
Dual GIP/GLP-1 receptor co-agonists
- Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) — Eli Lilly
Efficacy comparison — at-a-glance
Mean body-weight reduction in pivotal trials (higher = more weight loss):
- Tirzepatide (Mounjaro / Zepbound): ~22.5% at 72 weeks (SURMOUNT-1)
- Semaglutide 2.4mg (Wegovy): ~14.9% at 68 weeks (STEP-1)
- Semaglutide 1.0mg (Ozempic): ~6-8% at 68 weeks (varies by trial)
- Liraglutide 3.0mg (Saxenda): ~8% at 56 weeks (SCALE)
- Dulaglutide (Trulicity): ~3-5% (not a weight-loss-specific indication)
Dosing frequency comparison
- Once weekly: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Bydureon
- Once daily: Saxenda, Victoza
- Twice daily: Byetta (older formulation)
- Oral (daily): Rybelsus
Switching considerations
Switching within the same active ingredient
Switching between Mounjaro ↔ Zepbound (both tirzepatide), or Ozempic ↔ Wegovy (both semaglutide), or Victoza ↔ Saxenda (both liraglutide), is straightforward because the active ingredient is identical. The main differences are dose (Wegovy goes to 2.4mg vs Ozempic max ~2mg) and labeled indication (weight loss vs diabetes). Prescribers can transition without dose reset.
Switching between different active ingredients
Switching from semaglutide → tirzepatide (or vice versa), or to/from liraglutide, typically requires restarting titrationfrom the new drug's lowest dose. This is because:
- Different doses correspond to different molecular potencies
- Tolerability differs — even if you tolerated full-dose semaglutide, you may need to titrate up on tirzepatide
- Insurance coverage often requires fresh prior authorization for the new drug